PROCEPT BioRobotics Corp (PRCT) · Oct 2, 2026 · Exec change

PROCEPT BioRobotics adds cardiac-surgery veteran to board without changing strategy

Independent director appointed — Board expanded from 9 to 10 members

PROCEPT BioRobotics’ board appointment adds clinical and regulatory experience, but the filing brings no new guidance, deal, or operating change.

PROCEPT is scaling Aquablation and its HYDROS robotic platform for benign prostatic hyperplasia while building a longer-term prostate-cancer application around the same technology. Its 2026 plan emphasizes commercial expansion, procedure growth, international adoption and progress in the WATER IV prostate-cancer program.

The filing adds clinical credibility, not a new business initiative. The board increased its size from nine to ten directors and appointed Dr. Michael Mack, a veteran cardiac surgeon with extensive academic, surgical-trial and FDA-related leadership experience.

The fit is strategically relevant but indirect. Mack’s background in complex surgery, medical-device evaluation and clinical research could support PROCEPT as it seeks broader physician adoption and develops its prostate-cancer opportunity, but the 8-K does not announce a product decision, regulatory milestone, trial result or change in commercial plans. The company identifies its core business as urologic surgical robotics, with Aquablation for BPH and prostate cancer as a strategic adjacency.

There is no expectation-based upside to score. The appointment is independent, follows standard director compensation and indemnification terms, and includes no disclosed related-party arrangement. 〔0〕 That makes this a governance enhancement rather than a change to revenue, funding, guidance or execution.

Bottom line: This modestly strengthens PROCEPT’s clinical and regulatory bench as it expands beyond BPH, but it does not materially change the operating story today.وبه

Original filing on SEC EDGAR

More PROCEPT BioRobotics Corp news

PROCEPT BioRobotics adds cardiac-surgery veteran to board without changing strategy | PRCT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.